Professor of Medicine, St Louis University
Gastroenterology
Dr. Bruce R. Bacon, MD
|
|
Give Review
Bruce R. Bacon, MD is an expert in the field of Gastroenterology. He graduated from Case Western Reserve University School of Medicine. He received 3 awards: "Elected Member", "Top MD" and "Fellow (FACG)". Doctor Bruce R. Bacon, MD is a published physician. He has 80 publications published. The most current publication "Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network."
Publications
- Disparate access to treatment regimens in chronic Hepatitis C patients: data from the TRIO network.
- Accuracy of Fibroscan, Compared with Histology, in Analysis of Liver Fibrosis in Patients with Hepatitis B or C: A US Multi-center Study.
- Measurement of Hepatic Iron Concentration.
- The quality of care provided to patients with Varices in the department of veterans affairs.
- The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis.
- Boceprevir plus peginterferon α-2b/ribavirin in chronic Hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
- Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial.
- Adherence to assigned dosing regimen and sustained virological response among chronic Hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2...
- A global view of Hepatitis C: Physician knowledge, opinions, and perceived barriers to care.
- Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic Hepatitis C genotype 1 infection.
- Epoprostenol-Induced Hypersplenism in Portopulmonary Hypertension.
- Management of the treatment-experienced patient infected with Hepatitis C virus genotype 1: options and considerations.
- New therapies for Hepatitis C virus infection.
- Diagnosis and management of hemochromatosis: 2011 practice guidelines by the American association for the study of liver Diseases.
- Clinical trial report: treatment of nonalcoholic steatoHepatitis with vitamin E.
- Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic Hepatitis C.
- Quality of care in patients with chronic Hepatitis C virus infection: a cohort study.
- An explicit quality indicator set for measurement of quality of care in patients with Cirrhosis.
- Training in hepatology: where are we now?
- Moving the field of gastroenterology & hepatology forward.
- Retreating chronic Hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
- Lack of efficacy of maintenance interferon: results of the HALT-C Trial.
- Global transcriptional Response to Hfe deficiency and dietary iron overload in mouse liver and duodenum.
- Hereditary Hemochromatosis in the post-HFE era.
- Workforce issues in hepatology: what is needed?
- End-stage liver Disease in 2008: finally a glass half full.
- Hepatology: small steps forward.
- Treatment of Hepatitis C genotype 2/3.
- Clinical penetrance of hereditary Hemochromatosis.
- Making it happen: managed care considerations in vanquishing Hepatitis C.
- Into the light: strategies for battling Hepatitis C.
- Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic Hepatitis C virus.
- Subspecialty certification in transplant hepatology.
- The certificate of added qualification in transplant hepatology.
- Hepatology: where do we go from here?
- Splenectomy for thrombocytopenia in patients with hepatitis C Cirrhosis.
- Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells.
- Screening for Hemochromatosis.
- Pathophysiology of hereditary Hemochromatosis.
- Treatment issues with chronic Hepatitis C: special populations and pharmacy strategies.
- Chronic hepatitis C: an age wave of Disease burden.
- Effect of significant histologic steatosis or steatoHepatitis on response to antiviral therapy in patients with chronic Hepatitis C.
- Orchestration of iron homeostasis.
- Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary Hemochromatosis: a new role for magnetic resonance imaging.
- Relation of Hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention.
- HCV treatment in difficult patients: study three.
- HCV treatment in difficult patients: study four.
- HCV treatment in difficult patients: study one.
- HCV treatment in difficult patients: study two.
- Certificate of added qualification in transplant hepatology.
- Testing for Hepatitis C virus infection should be routine for persons at increased risk for infection.
- Pathogenesis of hereditary Hemochromatosis.
- Evaluation of serum anion gap in patients with liver Cirrhosis of diverse etiologies.
- Chronic Hepatitis C and normal ALT: considerations for treatment.
- Nonalcoholic steatoHepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
- Disease- and cell-specific expression of GP73 in human liver Disease.
- Managing Hepatitis C.
- Hepatitis C: a 20-year debt comes due.
- Treatment of nonalcoholic steatoHepatitis.
- Infection with Hepatitis C virus genotype 4 in the United States.
- Contribution of the H63D mutation in HFE to murine hereditary Hemochromatosis.
- Improved nonalcoholic steatoHepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
- Insurance, employment, and psychosocial consequences of a diagnosis of hereditary Hemochromatosis in subjects without end organ damage.
- Orlistat in the treatment of NASH: a case series.
- Effect of protein kinase C activation and inhibition on rat hepatic stellate cell activation.
- Treatment for chronic Hepatitis C.
- Concurrence of histologic features of steatohepatitis with other forms of chronic liver Disease.
- Budd-Chiari Syndrome and hepatocellular carcinoma: a case report and review of the literature.
- National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002.
- Decreased liver hepcidin expression in the Hfe knockout mouse.
- Treatment of patients with Hepatitis C and normal serum aminotransferase levels.
- Use of complementary and alternative medicine in patients with liver Disease.
- Targeted mutagenesis of the murine transferrin receptor-2 gene produces Hemochromatosis.
- Hepatic iron concentration does not influence Response to therapy with interferon plus ribavirin in chronic HCV infection.
- Pathogenesis of hereditary Hemochromatosis: genetics and beyond.
- Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary Hemochromatosis.
- Hereditary Hemochromatosis and alcohol: a fibrogenic cocktail.
- Cost-effectiveness of boceprevir in patients previously treated for chronic Hepatitis C genotype 1 infection in the United States.
Schools
Case Western Reserve University School of Medicine
Metro Health Medical Center
College of Wooster
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- Elected Member
- Top MD
- Fellow (FACG)
Education
-
Case Western Reserve University - MetroHealth -
Case Western Reserve University School of Medicine
Drug Facts
| NPI NUMBER | 1083622963 | |
| NPPES Provider LastName | BACON | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 631102540 | |
| NPPES Provider State | MO | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 2622.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 174.0 | |
| Percent Opioid Claims | 6.64 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083622963 |
| Last Name Of The Provider | BACON |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Abdul M. Swied, MD |
|
|
Dr. Sajidul H. Ansari, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alina Allen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William F. Stenson, MD |
|
Dr. David L. Ulrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard F. Huck Jr., MD |
|
|
Dr. Katie S. Roark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven A. Edmundowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry G. Perkins, MD |
|
|
Dr. John J. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason R. Taylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Kotner, MD
This Doctor is OpenDoctor Recommended.
|